DSNKY - Pfizer: Seriously Undervalued At Peak Pessimism
2024-06-23 11:13:33 ET
Summary
- Since the publication of my last article, Pfizer has continued to surprise me pleasantly.
- In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street.
- On June 14, 2024, the company announced promising results from a Phase 2 clinical trial, again demonstrating the clinical benefit of Elrexfio in the treatment of relapsed or refractory multiple.
- In addition, on April 26, the FDA approved Beqvez, a one-time gene therapy for treating adults with moderate to severe hemophilia B.
- With the company'sexpanding portfolio of drugs, coupled with improved margins in recent quartersand a decline in net debt, Pfizer is becoming an increasingly undervalued assetamong Big Pharma.
Since my last article , Pfizer's share price (NYSE: PFE ) has risen by over 10%, and I believe the bull run will continue....
Pfizer: Seriously Undervalued At Peak Pessimism